HC Wainwright Issues Positive Estimate for BLFS Earnings

BioLife Solutions, Inc. (NASDAQ:BLFS) – Investment analysts at HC Wainwright lifted their Q2 2026 earnings per share (EPS) estimates for BioLife Solutions in a research note issued on Thursday, July 23rd. HC Wainwright analyst Y. Chen now forecasts that the medical equipment provider will post earnings per share of ($0.01) for the quarter, up from their prior forecast of ($0.02). HC Wainwright has a “Neutral” rating and a $31.00 price target on the stock. The consensus estimate for BioLife Solutions’ current full-year earnings is $0.03 per share. HC Wainwright also issued estimates for BioLife Solutions’ FY2026 earnings at $0.03 EPS.

A number of other research firms have also recently commented on BLFS. TD Cowen cut shares of BioLife Solutions from a “buy” rating to a “hold” rating and dropped their price target for the stock from $33.00 to $31.00 in a research note on Wednesday. Craig Hallum lowered shares of BioLife Solutions from a “buy” rating to a “hold” rating and set a $31.00 price objective on the stock. in a research report on Wednesday. Zacks Research lowered shares of BioLife Solutions from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, May 12th. Jefferies Financial Group downgraded shares of BioLife Solutions from a “buy” rating to a “hold” rating and raised their price objective for the stock from $30.00 to $31.00 in a research note on Thursday. Finally, Lake Street Capital lowered BioLife Solutions from a “buy” rating to a “hold” rating and dropped their target price for the company from $33.00 to $31.00 in a research report on Wednesday. One investment analyst has rated the stock with a Buy rating, seven have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $31.43.

BioLife Solutions Stock Performance

Shares of BLFS opened at $29.98 on Monday. BioLife Solutions has a twelve month low of $17.86 and a twelve month high of $32.23. The company has a market cap of $1.46 billion, a P/E ratio of -374.70 and a beta of 1.94. The company’s fifty day simple moving average is $26.94 and its 200-day simple moving average is $23.53.

BioLife Solutions (NASDAQ:BLFS) last posted its quarterly earnings data on Thursday, May 7th. The medical equipment provider reported $0.04 EPS for the quarter, topping the consensus estimate of $0.01 by $0.03. BioLife Solutions had a negative net margin of 2.80% and a positive return on equity of 1.81%. The company had revenue of $27.50 million during the quarter, compared to analyst estimates of $25.66 million.

Hedge Funds Weigh In On BioLife Solutions

Institutional investors have recently modified their holdings of the stock. Jacobs Levy Equity Management Inc. bought a new stake in shares of BioLife Solutions during the first quarter valued at approximately $283,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in BioLife Solutions by 4.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,422 shares of the medical equipment provider’s stock valued at $489,000 after purchasing an additional 914 shares in the last quarter. Jane Street Group LLC purchased a new stake in shares of BioLife Solutions in the 1st quarter worth $1,091,000. Strs Ohio bought a new position in shares of BioLife Solutions during the 1st quarter worth $153,000. Finally, Qube Research & Technologies Ltd increased its stake in shares of BioLife Solutions by 2,399.5% during the second quarter. Qube Research & Technologies Ltd now owns 248,474 shares of the medical equipment provider’s stock valued at $5,352,000 after buying an additional 238,533 shares during the period. 93.24% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at BioLife Solutions

In related news, major shareholder Casdin Partners Master Fund, L sold 650,000 shares of the firm’s stock in a transaction dated Thursday, May 21st. The shares were sold at an average price of $23.70, for a total value of $15,405,000.00. Following the transaction, the insider owned 4,757,165 shares of the company’s stock, valued at $112,744,810.50. This trade represents a 12.02% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders have sold 1,200,000 shares of company stock valued at $28,125,000 in the last quarter. Corporate insiders own 2.20% of the company’s stock.

Trending Headlines about BioLife Solutions

Here are the key news stories impacting BioLife Solutions this week:

• Positive Sentiment: HC Wainwright reiterated a Neutral rating and a $31 price target while forecasting modest earnings growth for BioLife Solutions through 2027, which suggests analysts still see some upside from current levels. HC Wainwright earnings estimates and rating for BioLife Solutions
• Neutral Sentiment: Repligen’s planned acquisition of BioLife Solutions is being framed as strategically positive for Repligen’s cell therapy business, and the deal could provide a clear exit value for BLFS shareholders if completed. Zacks article on Repligen buying BioLife Solutions
• Negative Sentiment: Maxim Group downgraded BioLife Solutions (BLFS) from strong-buy to hold, adding pressure on the stock and signaling less enthusiasm from analysts. Maxim Group downgrade coverage via Zacks
• Negative Sentiment: Kahn Swick & Foti said it is investigating the adequacy of the price and process in BioLife’s proposed sale to Repligen, raising the risk of shareholder litigation or a challenged deal process. BusinessWire investor alert on BioLife Solutions sale investigation
• Negative Sentiment: TD Cowen also downgraded BioLife Solutions (BLFS) to hold, reinforcing the cautious tone around the stock after the acquisition announcement. TD Cowen downgrade on BioLife Solutions

BioLife Solutions Company Profile

BioLife Solutions (NASDAQ:BLFS) specializes in biopreservation and cold chain workflow solutions for cell and gene therapies, regenerative medicine and other advanced biologics. The company develops and markets proprietary cryopreservation media and technology platforms designed to maintain cell viability and functionality during processing, storage and transport. BioLife’s product portfolio addresses critical steps in the manufacturing and distribution of cell-based products, helping life science researchers and biopharmaceutical manufacturers protect and preserve living cells.

The company’s flagship offerings include CryoStor, a family of serum-free cryopreservation media; HypoThermosol, a hypothermic storage solution for short-term cell and tissue preservation; and the ThawSTAR system, an automated cell thawing instrument that delivers controlled and reproducible warming of frozen cell therapies.